Form 4: Director O'Connor Gains LMAT Equity Awards

Lemaitre Vascular Director John James O'Connor received restricted stock units and stock options as part of his compensation.

Summary

• Director John James O'Connor acquired 533 shares of Common Stock through a restricted stock unit (RSU) award on December 10, 2025.
• The RSU award vests 33 1/3% on December 1, 2026, with the remainder vesting in equal annual installments over the subsequent two years.
• O'Connor also acquired 3,431 stock options on December 10, 2025, with an exercise price of $83.66.
• These stock options vest over a three-year period, with 33 1/3% vesting on the first anniversary of the grant date (December 10, 2025), and the balance vesting in equal annual installments over the subsequent two years.
• The stock options expire on December 10, 2030.
• Following these transactions, O'Connor beneficially owns 62,340 shares of Common Stock and 3,431 stock options.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is generally a positive sign, indicating continued alignment of interests between management and shareholders. It's a routine compensation event rather than a significant market-moving announcement.

Positives

• Director O'Connor's acquisition of restricted stock units and stock options aligns his interests with long-term shareholder value.
• The awards are time-based, encouraging continued commitment to the company's performance over several years.

Future Outlook

The vesting schedules for both the restricted stock units and stock options indicate a long-term incentive structure for the director, aligning future performance with equity awards over the next three years.

Industry Context

This filing reflects a standard practice in the medical device industry, where executive and director compensation often includes equity awards like restricted stock units and stock options to incentivize long-term performance and align leadership interests with shareholder value. Such awards are common for retaining key talent and fostering commitment in a competitive sector.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options for director compensation is a common practice across the medical device industry, similar to companies like Medtronic (MDT) or Abbott Laboratories (ABT), which frequently use equity-based incentives to align executive and director interests with long-term company performance.
• The vesting schedule, typically over three years, is also standard for such awards, providing a sustained incentive for directors to contribute to the company's strategic goals and financial health.

Related Party Transactions

• John James O'Connor, a Director of Lemaitre Vascular Inc., received equity awards from the company as part of his compensation.

Stakeholder Impact

• Shareholders: The equity awards align the director's interests with long-term shareholder value, potentially leading to more focused strategic decisions aimed at increasing stock price.
• Employees: No direct impact on employees mentioned, but a stable and incentivized leadership can indirectly benefit overall company morale and direction.

Next Steps

• 33 1/3% of the restricted stock unit award will vest on December 1, 2026.
• The remaining balance of the restricted stock unit award will vest in equal annual installments over the subsequent two years.
• 33 1/3% of the stock options will vest on December 10, 2026 (first anniversary of grant date).
• The remaining balance of the stock options will vest in equal annual installments over the subsequent two years.
• The stock options will expire on December 10, 2030.

Key Dates

Recommendation

This Form 4 filing reports routine equity compensation for a director, which is a standard practice to align management interests with shareholders. It does not present new information that would fundamentally alter the investment thesis for Lemaitre Vascular Inc. Therefore, a 'hold' recommendation is appropriate, as the filing itself does not provide a strong catalyst for either buying or selling the stock, but rather confirms ongoing corporate governance practices.

Keywords

Lemaitre Vascular, LMAT, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Award, John James O'Connor